PHARMA MAR, S.A. «...1617181920...» Page 19 out of 24 24/11/2020 08:48 PHARMA MAR, S.A. On business and financial situation The Company reports that its subsidiary Genomica, S.A.U., has obtained a CE marking for a new multiviral PCR test for COVID-19, Influenza A and B and Respiratory Syncytial Virus (RSV) diagnostic. Register number: 5843 23/11/2020 17:40 PHARMA MAR, S.A. Other relevant information Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares. Register number: 5839 03/11/2020 08:08 PHARMA MAR, S.A. Interim management report La sociedad remite declaración intermedia de gestión del tercer trimestre de 2020 Register number: 5450 28/10/2020 19:27 PHARMA MAR, S.A. On financial instruments Implementation of the reduction of share capital by means of the redemption of own shares approved by the General Shareholders´ Meeting of 18 June 2020 under item number three of the agenda. Register number: 5331 28/10/2020 12:31 PHARMA MAR, S.A. Other relevant information The Company announces the judgement of the General Court of the European Union in relation to the refusal of the marketing authorisation for plitidepsin. Register number: 5307 15/10/2020 08:29 PHARMA MAR, S.A. On business and financial situation PharmaMar signs an agreement with Jazz Pharmaceuticals to commercialize lurbinectedin in Canada Register number: 5026 29/09/2020 19:11 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes - Liquidity and counterparty agreements The company reports the transactions performed in the context of the Share Buy-back Program between 23 September and 25 September 2020. Ending of the Share Buy-back Program and resumption of the liquidity agreement. Register number: 4737 23/09/2020 17:37 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The company reports the transactions performed in the context of the Share Buy-back Program between 16 September and 22 September 2020. Register number: 4597 17/09/2020 09:09 PHARMA MAR, S.A. On business and financial situation The Company has presented at the European Society of Medical Oncology (ESMO) Congress new results for lurbinectedin in sensitive patients with Small-Cell Lung Cancer, candidates for “re-challenge Register number: 4478 16/09/2020 17:42 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The company reports the transactions performed in the context of the Share Buy-back Program between 9 September and 15 September 2020. Register number: 4468 Page 19 out of 24 «...1617181920...»
